Phaseline

Companies › GuangZhou Cellgenes Biotechnology

GuangZhou Cellgenes Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Neurology, Other; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CG-BM1
Allogeneic human bone marrow mesenchymal stem cell injection
–Phase 1Ischemic Stroke or High-risk TIA (ABCD² ≥ 4); SarcopeniaDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07896941CG-BM1Phase 1Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)NeurologyDec 2028
NCT07865676CG-BM1Phase 1SarcopeniaOtherJun 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.